Business
Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04
FDA Minutes Reflect Constructive Dialogue and Successful Meeting Outcome with Alignment on Upcoming Phase 3 Clinical Trial Design for AD04 In Alcohol Use DisorderGLEN ALLEN, Va., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced receipt of the final meeting minutes from its End of Ph
About this update from Adial Pharmaceuticals, Inc
[{"type":"image","alt":"Adial Pharmaceuticals, Inc","displaySize":"","headline":null,"caption":"Adial Pharmaceuticals, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":282,"height":123,"url":"https://media.zenfs.com/en/globenewswire.com/1a7a0a453f63a638e99b1c536ceba3a8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fKhTAZbrVcry7QkXYXjJNA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/1a7a0a453f63a638e99b1c536ceba3a8","width":282,"height":123}},"lazy":false},{"type":"text","content":"FDA Minutes Reflect Constructive Dialogue and Successful Meeting Outcome with Alignment on Upcoming Phase 3 Clinical Trial Design for AD04 In Alcohol Use Disorder","length":162,"tagName":"p"},{"type":"text","content":"GLEN ALLEN, Va., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced receipt of the final meeting minutes from its End of Phase 2 (EOP2) Meeting with the U.S. Food and Drug Administration (FDA) held on July 29, 2025. The minutes provide the FDA’s formal input into the AD04 Phase 3 adaptive clinical trial design and broader clinical development strategy. This positive feedback marks a key milestone in advancing AD04 toward registration.","length":653,"tagName":"p"},{"type":"text","content":"The objective for the EOP2 Meeting was to align with the FDA on the design of the Phase 3 clinical development program for AD04, the Company’s lead investigational drug, a serotonin-3 receptor antagonist, being developed for the treatment of Alcohol Use Disorder (AUD) in individuals with heavy drinking and select genotypes. The discussion included key elements of the planned adaptive study design elements, such as target population, clinical endpoints, inclusion and exclusion criteria, dosing regimen, and affirmation of the biomarker-positive and biomarker-negative groups.","length":579,"tagName":"p"},{"type":"text","content":"Key Highlights from the FDA EOP2 Meeting:","length":41,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"FDA recognized AUD as an unmet need.","length":36,"tagName":"p"}]},{"val":[{"type":"text","content":"FDA supported Adial’s protocol and ...